CORDIS
EU research results

CORDIS

English EN

Host and viral factors in acute hepatitis C

Objective

Chronic hepatitis C is one of the most common chronic viral infections of humans and a major cause of chronic liver disease, cirrhosis and liver cancer. Still about 4 million new infections occur world-wide each year with 50-85% of patients progressing to chronic hepatitis C. Currently there is no marker to predict spontaneous viral clearance and to guide treatment decisions.
The major objectives of the HepaCute proposal are to develop biomarkers predicting the outcome of acute hepatitis C, improving the management of the related patients and thus decreasing the health burden of hepatitis C in Europe and Mediterranean partner countries (MPC).
The HepaCute consortium has evolved from a series of EC-funded projects on hepatitis C (HCVacc/HepCvax/Virgil/HEPACIVAC) and consists of world leading experts in HCV epidemiology, immunology, and virology, including partners from Egypt and Morocco, who have strongly influenced the current management of patients with acute hepatitis C in their respective regions, and contributed considerably to our understanding of mechanisms of spontaneous viral clearance. The HepaCute proposal is closely connected to ongoing national, European, and Egyptian networks on HCV research (HepNet, EASL, STDF), which will support HepaCute to make it a success.Together with another pertinent EU-funded research project, SPHINX, it actively contributes to coordinating EU-funded hepatitis C research with pertinent research projects funded in the MCP countries, in particular with hepatitis research projects funded under the Egyptian Science and Technology Development Fund (STDF).
Within HepaCute the most innovative technologies will be employed such as genome-wide association studies, transcriptomics, proteomics, and ultra-deep sequencing to better understand the early events in acute hepatitis C and to translate these results into readily practicable diagnostic tools to predict spontaneous viral clearance.
HepaCute has firmly integrated partners from Egypt and Morocco with preexisting research collaborations with European partners into the scientific research programm and we expect this continuing partnership between European and Mediterranean countries to have a strong impact on the care of patients with acute hepatitis C both in Europe and MPC.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

KLINIKUM DER UNIVERSITAT MUNCHEN

Address

Marchioninistrasse 15
81377 Munchen

Germany

Activity type

Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)

EU Contribution

€ 264 500

Administrative Contact

Renate Mueller (Ms.)

Participants (16)

Sort alphabetically

Sort by EU Contribution

Expand all

INSERM TRANSFERT SA

France

EU Contribution

€ 165 965

MEDIZINISCHE HOCHSCHULE HANNOVER

Germany

EU Contribution

€ 197 000

UNIVERSITAETSKLINIKUM FREIBURG

Germany

EU Contribution

€ 148 000

AZIENDA OSPEDALIERO-UNIVERSITARIA DI PARMA

Italy

EU Contribution

€ 286 500

FUNDACION PARA LA INVESTIGACION MEDICA APLICADA FIMA

Spain

EU Contribution

€ 172 500

UNIVERSITE DE GENEVE

Switzerland

EU Contribution

€ 69 000

THE UNIVERSITY OF BIRMINGHAM

United Kingdom

EU Contribution

€ 335 500

IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE

United Kingdom

EU Contribution

€ 226 035

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

France

EU Contribution

€ 264 500

MOSAIQUES DIAGNOSTICS GMBH

Germany

EU Contribution

€ 123 000

THE HOLDING COMPANY FOR BIOLOGICAL PRODUCTS & VACCINES LLC

Egypt

EU Contribution

€ 168 000

MENOUFIYA UNIVERSITY

Egypt

EU Contribution

€ 82 000

National Research Center

Egypt

EU Contribution

€ 142 000

CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS

Switzerland

EU Contribution

€ 148 000

KLINIKUM DER UNIVERSITAET ZU KOELN

Germany

EU Contribution

€ 118 000

Institut Pasteur Du Maroc

Morocco

EU Contribution

€ 89 000

Project information

Grant agreement ID: 260844

Status

Closed project

  • Start date

    1 November 2010

  • End date

    30 April 2014

Funded under:

FP7-HEALTH

  • Overall budget:

    € 3 854 861,40

  • EU contribution

    € 2 999 500

Coordinated by:

KLINIKUM DER UNIVERSITAT MUNCHEN

Germany